215 related articles for article (PubMed ID: 21278395)
1. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
2. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
3. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
4. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
5. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
6. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
7. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Ianotto JC; Tempescul A; Amet Y; Grall P; Dalbies F; Eveillard JR; Guillerm G; Berthou C
Am J Hematol; 2012 Apr; 87(4):437-9. PubMed ID: 22287505
[No Abstract] [Full Text] [Related]
9. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
10. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
11. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
Yu YH; Shere Y; Vigneswaran N
Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661
[No Abstract] [Full Text] [Related]
12. [Adverse effects of imatinib mesylate].
Isshiki I
Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
[No Abstract] [Full Text] [Related]
13. Imatinib and regression of type 2 diabetes.
Veneri D; Franchini M; Bonora E
N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
[No Abstract] [Full Text] [Related]
14. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
15. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Ault P; Kantarjian H; Welch MA; Giles F; Rios MB; Cortes J
Leuk Res; 2004 Jun; 28(6):613-8. PubMed ID: 15120938
[TBL] [Abstract][Full Text] [Related]
17. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
19. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate induced skin hypopigmentation.
Talwar V; Doval DC; Bhatia K
J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
[No Abstract] [Full Text] [Related]
[Next] [New Search]